

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
34180	13/NW/0208	121193	NCRN568 - ARROVEN - brentuximab vedotin PASS	Number Agreed	18	18	Date Agreed	26/06/2018	14	26/06/2018	14	Recruitment Finished	
34181	15/SW/0196	181754	CANC - 4663 - Phase III Study of MPDL3280A in Stage IV Non-Squamous NSCLC	Number Agreed	2	2	Date Agreed	31/08/2016	5	02/02/2018	5	Recruitment Finished	
34182	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	4	4	Date Agreed	01/07/2017	4	19/10/2018	4	Recruitment Finished	
34183	15/SW/0248	186033	VX14-661-110 Cystic Fibrosis	Number Agreed	3	3	Date Agreed	16/07/2018	10	30/06/2018	10	Recruitment Finished	
34184	15/LO/2045	193136	CHIL 5229 SMT C1100 in Ambulatory Boys with DMD	Number Agreed	2	2	Date Agreed	02/03/2017	5	27/06/2018	5	Recruitment Finished	
34185	15/EM/0521	184930	CANC - 5309	Number Agreed	4	4	Date Agreed	31/07/2018	5	22/06/2018	5	Recruitment Finished	
34186	16/EM/0343	199239	RE-COVERY DVT/PE	Number Agreed	30	30	Date Agreed	30/09/2017	177	28/02/2018	177	Recruitment Finished	
34187	16/EM/0037	196490	MUSC 4598	Number Agreed	4	4	Date Agreed	19/12/2017	2	30/01/2018	2	Recruitment Finished	
34188	17/LO/0100	200545	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens	Number Agreed	2	2	Date Agreed	31/05/2018	0	26/03/2018	0	Recruitment Finished	
34189	13/NW/0003	117310	SEVERE SEPSIS / COAGULOPATHY TRIAL ART-123	Number Agreed	3	3	Date Agreed	31/08/2017	2	08/03/2018	2	Recruitment Finished	
34190	16/WM/0108	195179	CHIL 4885	Number Agreed	5	5	Date Agreed	01/07/2018	0	18/01/2018	0	Withdrawn By Host	Issues with pharmacy and labelling
34191	16/EM/0167	179908	RESP 4602	Number Agreed	3	3	Date Agreed	31/01/2019	1	16/07/2018	1	Recruitment Finished	
34192	16/WM/0395	210507	RENA 4591 (ASCEND-D)	Number Agreed	4	4	Date Agreed	26/04/2018	2	07/06/2018	2	Recruitment Finished	
34193	15/WS/0170	184797	HAEM 4528	Number Agreed	4	4	Date Agreed	19/01/2019	7	07/09/2018	7	Recruitment Finished	
34194	15/NW/0586	184456	CARD 4754	Number Agreed	20	20	Date Agreed	31/03/2018	13	26/01/2018	13	Recruitment Finished	
34195	16/EM/0439	199809	NOVELTY	Number Agreed	48	48	Date Agreed	30/11/2020	19	05/03/2018	19	Recruitment Finished	
34196	15/EM/0500	188865	RESP 4446	Number Agreed	2	2	Date Agreed	20/09/2017	0	20/09/2018	0	Recruitment Finished	
34197	16/WM/0507	218607	EXCEED	Number Agreed	4	4	Date Agreed	01/06/2018	2	23/08/2018	2	Recruitment Finished	
34198	17/LO/0441	222471	MK-3475-604 (Phase 3 trial of etoposide/platinum with or without pembrolizumab)	Number Agreed	4	4	Date Agreed	30/09/2021	1	09/07/2018	1	Recruitment Finished	
34199	17/WA/0183	225334	M16-043 Phase 3 patients with treatment naive AML	Number Agreed	2	2	Date Agreed	22/08/2019	3	19/04/2018	3	Recruitment Finished	
34200	17/NE/0151	223815	SGL-110 vs Treatment Choice in Adults with Previously Treated AML	Number Agreed	2	2	Date Agreed	29/09/2018	3	17/09/2018	3	Recruitment Finished	
34201	18/HRA/0198	233095	Real world Alirocumab Use in the UK	Number Agreed	30	30	Date Agreed	20/11/2017	30	26/03/2018	30	Recruitment Finished	
34202	16/SC/0035	194232	A Phase III Study of Pembrolizumab vs. Chemotherapy in MSI-H or dMMR S	Number Agreed	3	3	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment Finished	
34203	17/NS/0098	233221	SAGE-Observational study of glycaemic control & QoL in Type 1 diabetes	Number Agreed	20	20	Date Agreed	30/04/2018	21	03/05/2018	21	Recruitment Finished	
34204	17/NW/0584	233211	Study of Serlopitant for the Treatment of Refractory Chronic Cough	Number Agreed	5	5	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment Finished	
34205	17/EM/0425	236800	Retrospective review of current treatment pathways for MF in the UK	Number Agreed	15	15	Date Agreed	31/01/2018	19	30/04/2018	19	Recruitment Finished	
34206	16/LO/1709	212830	Semaglutide in NASH	Number Agreed	2	2	Date Agreed	19/11/2018	0	12/07/2018	0	Recruitment Finished	Sponsor closed study earlier than expected, which impacted recruitment
34207	18/SC/0098	241440	Subcut Daratumumab in combination with standard treatment regimens	Number Agreed	3	3	Date Agreed	27/10/2020	5	19/07/2018	5	Recruitment Finished	
34208	18/NE/0200	244356	VX17-445-102 Efficacy and Safety of VX-445/TEZ/IVA in CF Het-min	Number Agreed	3	3	Date Agreed	30/06/2019	2	22/08/2018	2	Recruitment Finished	Sponsor closed study earlier than expected, which impacted recruitment
34209	18/NE/0201	244419	VX17-445-103 Efficacy and Safety of VX-445/TEZ/IVA in CF Homozygous	Number Agreed	3	3	Date Agreed	31/01/2019	2	02/11/2018	2	Recruitment Finished	Sponsor closed study earlier than expected, which impacted recruitment
34210	17/NW/0656	235797	ODYSSEY LEGACY.	Number Agreed	21	21	Date Agreed	31/12/2018	16	05/09/2018	16	Withdrawn By Sponsor	Sponsor faced challenges with trial, and so withdrew the trial internationally.
34211	18/LO/1002	242654	Study of GSK2857196 in pts. with RRMM who have failed on Daratumumab	Number Agreed	2	2	Date Agreed	07/12/2018	1	19/10/2018	1	Recruitment Finished	
34212	18/HRA/1748	243170	Venetoclax (ABT-199)	Number Agreed	3	3	Date Agreed	06/08/2018	3	06/08/2018	3	Recruitment Finished	